A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

Summary

This is a study of LY4337713 in participants with certain types of cancer that is advanced or has spread. Participants must have cancer with high levels of a protein called fibroblast activation protein (FAP). The purpose of this study is to evaluate safety, side effects, and efficacy of LY4337713. In addition, this study will evaluate how much LY4337713 gets into the bloodstream, how it is broken down, and how long it takes the body to get rid of it. For each participant, the study will last about 5 years.

Interventions

• LY4337713 · DRUG

  Administered IV.

Published eligibility criteria

Verbatim from the registry. Only the site can decide how these apply to a specific patient.

Inclusion Criteria:

* Must have clinical or imaging evidence of fibroblast activation protein (FAP) expression per local assessment
* Must have histologically or cytologically confirmed diagnosis of one of the following:

  * Adenocarcinoma of the pancreas
  * Hormone receptor (HR)-positive human epidermal growth factor 2 (HER2)-negative breast cancer
  * HER2-positive breast cancer
  * Triple negative breast cancer (TNBC)
  * Platinum-resistant or refractory ovarian cancer (including ovarian carcinosarcoma)
  * Other solid tumors

    * Gastric cancer (adenocarcinoma)
    * Colorectal cancer (CRC)
    * Esophageal cancer (squamous cell carcinoma or adenocarcinoma)
    * Cholangiocarcinoma
* Must have received prior treatments as indicated below:

  * Phase 1a

    * Adenocarcinoma of the pancreas: Participants must have received at least 1, but no more than 2 prior regimens for locally advanced unresectable or metastatic disease.
    * HR-positive HER2-negative breast cancer: Participants must have received less than or equal to (≤)5 prior lines of treatment for advanced or metastatic disease, which must include a cyclin-dependent kinase 4/6 inhibitor.
    * HER2-positive breast cancer: Participants must have received at least 2 lines of HER2-targeted therapy, which should include at least 1 antibody-drug conjugate (ADC) for metastatic disease (if locally available).
    * TNBC: Participants must have received at least 2 lines of therapy for metastatic disease.
    * Platinum-resistant or refractory ovarian cancer: Participants must have received or after at least 1 platinum-based therapy.
    * Other solid tumors (gastric cancer, CRC, esophageal and cholangiocarcinoma): Participants must have received greater than or equal to (≥)1 prior line of systemic therapy for advanced or metastatic disease; including prior line(s) in combination with immunotherapy or vascular endothelial growth factor inhibitor.
  * Phase 1b:

    * Participants must have advanced or metastatic solid tumors and have received ≥1 prior line of therapy.
* Must have an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 1.
* Measured creatinine clearance ≥60 milliliters per minute (mL/min)

Exclusion Criteria:

* Have known active central nervous system (CNS) metastases or carcinomatous meningitis.
* Have significant cardiovascular disease
* Have prolongation of the corrected QTcF \>470 milliseconds (msec) during screening. QTcF is calculated using Fridericia's Formula: QTcF = QT/(RR0.33)
* Have evidence of ongoing and untreated urinary tract obstruction
* Had previous hemi- or total-body radiation.
* Had previous adoptive T-cell therapy (e.g., chimeric antigen receptor T-cell \[CAR-T therapy, T-cell receptor \[TCR\] therapy, etc.)
* Unable to lie flat during, or otherwise tolerate, single photon emission computed tomography (SPECT), positron emission tomography (PET), computed tomography (CT) or magnetic resonance imaging (MRI).

Sites (30)

• Hoag Memorial Hospital Presbyterian, Newport Beach, California · RECRUITING
• Stanford University Medical Center, Stanford, California · RECRUITING
• Biogenix Molecular, LLC, Miami, Florida · COMPLETED
• Moffitt, Tampa, Florida · RECRUITING
• Indiana University (IU) School of Medicine, Indianapolis, Indiana · RECRUITING
• United Theranostics, Glen Burnie, Maryland · RECRUITING
• Massachusetts General Hospital, Boston, Massachusetts · RECRUITING
• Beth Israel Deaconess Medical Center, Boston, Massachusetts · NOT_YET_RECRUITING
• Barbara Ann Karmanos Cancer Institute, Detroit, Michigan · RECRUITING
• BAMF Health Inc., Grand Rapids, Michigan · RECRUITING
• Mayo Clinic - Rochester, Rochester, Minnesota · NOT_YET_RECRUITING
• Washington University School of Medicine in St. Louis, St Louis, Missouri · NOT_YET_RECRUITING
• New York University (NYU) Clinical Cancer Center, New York, New York · RECRUITING
• David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York, New York · RECRUITING
• Duke University Medical Center, Durham, North Carolina · RECRUITING
• University of Pennsylvania, Philadelphia, Pennsylvania · RECRUITING
• Fox Chase Cancer Center, Philadelphia, Pennsylvania · RECRUITING
• Texas Oncology - DFW (Sammons CC), Dallas, Texas · RECRUITING
• Baylor College of Medicine, Houston, Texas · NOT_YET_RECRUITING
• University of Wisconsin - Carbone Cancer Center, Madison, Wisconsin · RECRUITING
• Fudan University Zhongshan Hospital, Shanghai, China · NOT_YET_RECRUITING
• Universitaetsklinikum Essen, Essen, Germany · NOT_YET_RECRUITING
• National Cancer Center Hospital East, Chiba, Japan · NOT_YET_RECRUITING
• Kyoto University Hospital, Kyoto, Japan · NOT_YET_RECRUITING
• Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis (NKI-AVL), Amsterdam, Netherlands · NOT_YET_RECRUITING
• Amsterdam UMC - Locatie VUmc, Amsterdam, Netherlands · NOT_YET_RECRUITING
• Erasmus MC, GE Rotterdam, Netherlands · NOT_YET_RECRUITING
• Maastricht University Medical Center, Maastricht, Netherlands · NOT_YET_RECRUITING
• Stichting Radboud Universitair Medisch Centrum, Nijmegen, Netherlands · NOT_YET_RECRUITING
• Universitair Medisch Centrum Utrecht, Utrecht, Netherlands · NOT_YET_RECRUITING